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Introduction {#sec001}
============

Oxidative stress is a pathophysiological mechanism potentially involved in schizophrenia \[[@pone.0194685.ref001]--[@pone.0194685.ref005]\]. There is evidence that patients who have experienced just a single episode of psychosis have increased levels of lipid peroxidation \[[@pone.0194685.ref006]--[@pone.0194685.ref009]\] and a decreased total antioxidant capacity \[[@pone.0194685.ref010]\].

The total antioxidant activity of extracellular fluid can be calculated by adding endogenous and food-derived antioxidants. Total antioxidant status (TAS) is considered to have great potential in the search for biomarkers of functional damage in psychiatric disorders, given its association with the pathophysiology of schizophrenia spectrum disorders \[[@pone.0194685.ref001]--[@pone.0194685.ref003]\].

A number of case-control studies have been conducted to assess TAS using a cross-sectional method \[[@pone.0194685.ref010]--[@pone.0194685.ref013]\]. However, very few studies have explored the relation between TAS and the functionality of patients over time, with inconsistent results \[[@pone.0194685.ref012],[@pone.0194685.ref014]--[@pone.0194685.ref016]\]. In addition, there are no published data on TAS at the onset of psychotic illness.

The objective of our study was to assess the relationship between total antioxidant status (TAS) and the functional status of patients with a first episode of psychosis (FEP), at the early course of the disease. We hypothesized that antioxidant status would be associated with both, the short and long-term functioning and clinical outcome in these patients.

Materials and methods {#sec002}
=====================

Study population {#sec003}
----------------

The child and adolescent first-episode psychosis study (CAFEPS) is a cohort study that included 110 patients with FEP aged between nine and 17 years at first assessment. FEP was defined as the presence of positive psychotic symptoms of delusions or hallucinations for a period of less than six months. The exclusion criteria for the patients were: presence of a concomitant Axis I disorder at the time of evaluation that might account for the psychotic symptoms (such as substance abuse, autistic spectrum disorders, post-traumatic stress disorder, or acute stress disorder), mental retardation (MR) per the DSM-IV criteria, including not only an IQ below 70 but also impaired functioning, pervasive developmental disorder, neurological disorders, history of head trauma with loss of consciousness, and pregnancy. Occasional substance use was not an exclusion criterion if positive symptoms persisted for more than 2 weeks after a negative urine drug test. Information about the sample and protocol has been described in detail elsewhere \[[@pone.0194685.ref017]\]. The study was approved by the Clinical Research Ethics Committee of all participating hospitals: Ethics and Clinical Research Boards of Gregorio Marañón General University Hospital, Clinical Research Ethics Committee of the Hospital Clínic de Barcelona, Clinical Research Ethics Committee of Euskadi, Clinical Research Ethics Committee of University of Navarra Clinic, Bioethics Committee of the Marqués de Valdecilla University Hospital and the Clinical Research Ethics Committee of Niño Jesús University Children\'s Hospital. Parents or legal guardians gave written informed consent and patients consented to participate in the study.

Study design and clinical assessments {#sec004}
-------------------------------------

We conducted a prospective two-year follow-up study to assess the TAS and clinical status of FEP patients at three time points (at baseline and at one and two years). Clinical assessment was performed by trained clinicians who used the following scales: 1) the Spanish version of the Positive and Negative Syndrome Scale (PANSS)\[[@pone.0194685.ref018]\], which measures the severity of these types of symptoms; 2) the Hamilton Rating Scale for Depression (HRSD) \[[@pone.0194685.ref019]\], which measures the severity of depressive symptoms; 3) the Young Mania Rating Scale (YMRS), which measures the severity of manic symptoms \[[@pone.0194685.ref020]\]; and 4) the Children\'s Global Assessment Scale (CGAS) \[[@pone.0194685.ref021]\], which rates a patient's level of functioning and severity of symptoms on a scale of 0 to 100.

Assessment of TAS {#sec005}
-----------------

Total antioxidant capacity was assessed by measuring TAS in peripheral blood at the aforementioned three time points. Blood samples (10ml) were collected in heparin-containing tubes after enrolment between 8:00 and 10:00 ~AM~ and were immediately processed as follows: tubes were centrifuged for 5 min at 400 g at 4°C. Plasma was collected and centrifuged for 15 min at 14,000 g at 4°C and then stored at -80°C until analysis. All samples were analyzed in a single batch. Baseline data has been published previously by Micó et al. \[[@pone.0194685.ref010]\]. For the present study, we only used baseline data from the subset of patients who were followed up. TAS was determined by standardized spectrophotometric assays (Bioxytech) in plasma. Briefly, the TAS assay relies on the ability of antioxidants present in plasma to inhibit the oxidation of ABTS (2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonicacid)), which is monitored by reading absorbance at 600 nm \[[@pone.0194685.ref022]\].

Statistical analysis {#sec006}
--------------------

After confirming the normality of sociodemographic and clinical data, a descriptive analysis was performed using means, standard deviation, and percentages. Analysis of variance (ANOVA) with repeated measures (measuring within subject variables) were used to analyse the main effect of time on TAS level, clinical parameters and antipsychotic dose. To investigate if some of the potential confounding factors (age, sex, ethnic group, diagnostic group, parental level of education, socioeconomic level, living arrangements, use of toxic substances and dose of medication in chlorpromazine equivalent unit) had influence on TAS levels in each visit, different statistical models were employed: T-student model for independent samples with categorical variables of two groups, analysis of variance (ANOVA) for categorical variables of more than two groups and bivariate Pearson correlation to compare continuous variables. To evaluate the relationship between TAS and clinical variables, linear regressions were performed and adjusted for the potentially confounding variables that revealed significant in the previous step. The final models contained (significant) confounding variables and the interaction of independent variables with these confounding variables was also included. To evaluate the relationship between TAS and scores on clinical scales, differential variables between baseline and 1-year/2-year values were calculated and linear regressions were performed. In addition, we used longitudinal linear models to analyse the relationship between the evolution of TAS and changes in clinical scale scores. These models were created in two steps: 1) we analysed the influence of the potential confounding variables on the evolution of TAS; 2) we defined the final models by including the variables that revealed significant in the first step and the clinical scales. Data are presented in terms of beta coefficients with *p* values and the corresponding 95% confidence intervals. The distribution of clinical variables was grouped in different percentiles to assess dose-response in the relation between clinical variables and TAS. All statistical analyses were carried out using SPSS v23.0 statistical software, with the significance level set at *p* \<0.05.

Results {#sec007}
=======

Characteristics of the sample {#sec008}
-----------------------------

Of the 110 patients initially included in the study, 70 were selected to compose the final sample, as they had attended the baseline visit and at least the first follow-up visit. At the end of the study, there was a 35% reduction in the size of the sample with respect to the sample of the first follow-up year. The characteristics of the entire sample are detailed in [Table 1](#pone.0194685.t001){ref-type="table"}. No significant changes were found in antipsychotic dose over time (F = 1.22; p\>0.05). The scores obtained on the various scales are summarised in [Table 2](#pone.0194685.t002){ref-type="table"}, which shows that scores had improved significantly on all scales at the end of the study (p\<0.01).

10.1371/journal.pone.0194685.t001

###### Sociodemographic characteristics and total antioxidant status (TAS).

![](pone.0194685.t001){#pone.0194685.t001g}

  *Sociodemographic characteristics*                                *Patients (N = 70)*
  ----------------------------------------------------------------- ---------------------
  Age in years, n (SD)                                              15.70 (1.63)
  Sex (M/F), mean (%)                                               50 (71.4)/20(28.6)
  Drug use, n baseline (%)                                          
  Tobacco                                                           20 (28.6)
  Cannabis                                                          20 (28.6)
  Alcohol                                                           17 (24.3)
  Socioeconomic status, n (%)                                       
  5 (lowest)                                                        14 (20.0)
  4                                                                 23 (32.9)
  3                                                                 18 (25.7)
  2                                                                 6 (8.6)
  1 (highest)                                                       9 (12.9)
  Type of living arrangement, n (%)                                 
  Birth parents                                                     64 (91.4)
  Alone                                                             1 (1.4)
  Other                                                             5 (7.2)
  Ethnic group, n (%)                                               
  Caucasian                                                         64 (91.4)
  Hispanic                                                          4 (5.7)
  Other                                                             2 (2.9)
  Antipsychotic dose (chlorpromazine equivalent units), mean (SD)   
  Baseline                                                          260.66 (170.76)
  1 year                                                            267,99 (234,77)
  2 years                                                           213,42 (133,11)
  *Variables related to oxidative stress*                           
  TAS (mM), mean (SD)                                               
  Baseline                                                          0.95 (0.30)
  1 year                                                            0.99 (0.42)
  2 years                                                           1.14 (0.36)

10.1371/journal.pone.0194685.t002

###### Scores in the clinical assessments at the three time points.

![](pone.0194685.t002){#pone.0194685.t002g}

                                                                *Clinical assessment*                  
  ------------------------------------------------------------- ----------------------- -------------- ---------------
  PANSS Pos, mean (SD)[\*\*](#t002fn002){ref-type="table-fn"}   24.2 (6.16)             12.63 (6.0)    12.11 (5.47)
  PANSS Neg, mean (SD)[\*\*](#t002fn002){ref-type="table-fn"}   21.07 (8.83)            16.54 (6.6)    14.69 (6.40)
  PANSS Gen, mean (SD)[\*\*](#t002fn002){ref-type="table-fn"}   47.01 (10.77)           29.63 (11.1)   27.46 (8.17)
  PANSS Tot, mean (SD)[\*\*](#t002fn002){ref-type="table-fn"}   92.3 (20.41)            58.80 (20.7)   54.27 (17.54)
  YMRS, mean (SD)[\*\*](#t002fn002){ref-type="table-fn"}        17.77 (11.46)           4.90 (7.6)     4.04 (5.20)
  HDRS, mean (SD)[\*\*](#t002fn002){ref-type="table-fn"}        19.31 (9.26)            5.76 (6.9)     4.88 (3.99)
  CGAS, mean (SD)[\*\*](#t002fn002){ref-type="table-fn"}        37.41 (14.22)           63.52(16.9)    67.11(18.13)

\*p\<0.05

\*\*p\<0.01

Pos (positive), Neg (negative), Gen (General), Tot (total)

Relationship between oxidative stress and clinical assessment {#sec009}
-------------------------------------------------------------

### Comparison of TAS among assessments {#sec010}

TAS improved progressively over the two years of follow-up, although none of the differences observed among the values measured at the three time points reached significance ([Table 1](#pone.0194685.t001){ref-type="table"}). None of the potential confounding factors had a significant influence on TAS levels ([S1 Table](#pone.0194685.s001){ref-type="supplementary-material"}).

### Relationship between TAS and clinical variables {#sec011}

None of the variables included in the linear regression model as potential confounding factors were significant; hence, only clinical variables were included in the final model. At baseline, there was a significant positive relationship between TAS and CGAS scores. In contrast, at one year, this association was reversed, and TAS and YMRS and positive PANSS scores were observed to be all positively related. At two-year follow-up, TAS was significantly negatively correlated to CGAS scores and positively associated with YMRS, positive PANSS, negative PANSS, general PANSS and total PANSS scores ([Table 3](#pone.0194685.t003){ref-type="table"}; [Fig 1](#pone.0194685.g001){ref-type="fig"}; [S1](#pone.0194685.s002){ref-type="supplementary-material"} and [S2](#pone.0194685.s003){ref-type="supplementary-material"} Figs). No correlation based on differential variables was observed between changes in TAS and variations in clinical scale scores. However, longitudinal linear models confirmed the previous observation of a relationship between TAS and CGAS (β = -0.006, p = 0.004, 95% CI: (-0.010, -0.002)), PANSS pos (β = 0.013, p = 0.040, 95% CI: (0.001, 0.025)) and YMRS scales (β = 0.014, p = 0.007, 95% CI: (0.004, 0.025)) after adjusting for gender. When CGAS were distributed in percentiles to analyse dose-response in this relation, a monotonic increase of the TAS was observed, with higher CGAS at baseline. In contrast, at one and two year follow-up, this monotonic effect was also significant, with a negative relationship between TAS values and CGAS ([Table 4](#pone.0194685.t004){ref-type="table"}).

![Relationship between total antioxidant status (TAS) and Children\'s Global Assessment Scale (CGAS) scores over a two year follow-up.](pone.0194685.g001){#pone.0194685.g001}

10.1371/journal.pone.0194685.t003

###### Coefficients of linear regression models between clinical assessment and TAS level at each visit point.

![](pone.0194685.t003){#pone.0194685.t003g}

  *Clinical assessment*   *TAS*                                      
  ----------------------- -------------------- --------------------- ---------------------
  PANSS Pos               ---                  B = 0.024; p\<0.05    B = 0.030; p\<0.05
  PANSS Neg               ---                  ---                   B = 0.025; p\<0.05
  PANSS Gen               ---                  ---                   B = 0.021;p\<0.05
  PANSS Tot               ---                  ---                   B = 0.011; p\<0.01
  YMRS                    ---                  B = 0.018; p\<0.05    B = 0.027; p = 0.05
  HDRS                    ---                  ---                   ---
  CGAS                    B = 0.005; p\<0.05   B = -0.011; p\<0.01   B = -0.009; p\<0.05

Pos (positive), Neg (negative), Gen (General), Tot (total)

10.1371/journal.pone.0194685.t004

###### Effect size of CGAS on TAS (and 95% CIs).

![](pone.0194685.t004){#pone.0194685.t004g}

            *BASELINE*   *1 YEAR*              *2 YEAR*                                   
  --------- ------------ --------------------- ---------- ------------------------ ------ ------------------------
  **P3**    15           0.08 (0.002, 0.148)   35         -0.39 (-0.626, -0.144)   35     -0.32 (-0.573, -0.068)
  **P25**   30           0.15 (0.003, 0.297)   50         -0.55 (-0.894, -0.206)   51     -0.46 (-0.828, -0.092)
  **P50**   40           0.20 (0.004, 0.396)   63         -0.69 (-1.124, -0.256)   70.5   -0.64 (-1.149, -0.131)
  **P75**   45           0.23 (0.010, 0.450)   80         -0.88 (-1.431, -0.329)   85     -0.77 (-1.383, -0.157)
  **P97**   60           0.33 (0.012, 0.648)   95         -1.05 (-1.704, -0.396)   95     -0.86 (-1.545, -0.175)

Discussion {#sec012}
==========

To our knowledge, this is the first study to investigate the relationship between the antioxidant defence system and clinical and functional status in a sample of adolescents with FEP over time. Interestingly, the antioxidant reserve was smaller in the most severe cases at baseline, and higher in the most severe cases at follow-up, which may be the result of an adaptation of the antioxidant defence system in the long term. Specifically, we found that patients with the most severe positive psychotic symptoms and a worse functionality over two-year follow-up, exhibited higher levels of antioxidants as shown by the results obtained in the longitudinal linear models. These results are unlikely to be due to chance, as there is a monotonic increase in TAS levels at baseline with respect to functionality, and a monotonic decrease of TAS levels with respect to functionality over time ([Fig 2](#pone.0194685.g002){ref-type="fig"}).

![Relationship between CGAS score and TAS level at baseline and at two-year follow-up assessment.\
a) At baseline, there is a positive significant relationship between CGAS and TAS indicating that the better the patient\'s functioning, the higher his level of TAS; b) at one year and at two years of follow-up, this relationship is significantly reversed, with patients with the highest levels of TAS having the worst functionality.](pone.0194685.g002){#pone.0194685.g002}

We found no previous studies analysing these variables in children, and only Zhang et al. \[[@pone.0194685.ref012]\] have assessed the association between cognitive impairment and TAS in adult patients with schizophrenia. The authors observed that these variables were negatively correlated. In line with this, a previous study by Sánchez-Rodríguez et al. \[[@pone.0194685.ref015]\] comparing elderly people living in rural and urban areas revealed a significant negative relationship between cognitive performance and TAS, with those with the most severe cognitive impairment (lowest scores) having higher TAS.

The classical theory of hormesis suggests that short exposure to a low level of stress triggers protection mechanisms that help biological systems to recover baseline levels and cope better with high levels of stress \[[@pone.0194685.ref023]\]. In other words, it induces a homeostatic effect. This theory is also supported by some authors who have hypothesised that the greater the damage caused by oxidative stress in cells, the higher the antioxidant capacity of the organism \[[@pone.0194685.ref012],[@pone.0194685.ref015],[@pone.0194685.ref024],[@pone.0194685.ref025]\]. At cellular level, these compensatory mechanisms occur through enzymatic regulation, which stimulates antioxidant response, thus increasing defence capacity mediated by the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) \[[@pone.0194685.ref023],[@pone.0194685.ref026],[@pone.0194685.ref027]\]. Some studies have suggested that the activation of Nrf2 may reduce the susceptibility of neurons, astrocytes, oligodendrocytes and microglia to oxidative damage, and this is of great importance for potential therapeutic strategies \[[@pone.0194685.ref028],[@pone.0194685.ref029]\].

Although it is uncertain that changes in peripheral TAS levels reflect TAS variations in the central nervous system, the evidence obtained in our study supports the use of peripheral TAS markers in patients with first-episode psychosis, based on the special sensitivity of the brain to oxidative damage \[[@pone.0194685.ref030]\]. In addition, recent studies have revealed that plasma markers correlate to cerebrospinal fluid \[[@pone.0194685.ref031]\]and postmortem brain tissue \[[@pone.0194685.ref032]\] markers, which is suggestive of a parallel and synchronized activity between the peripheral and central systems \[[@pone.0194685.ref033]\].

Our study has several limitations and strengths. A limitation is related to the follow-up of patients. This being a two-year longitudinal study of children and adolescents, follow-up of all patients was difficult. On the other hand, the strengths of the study include that the sample was highly homogeneous in terms of age, duration of the illness, and pharmacological treatment, and that a long-term follow-up was conducted. Further longitudinal studies should be performed in the future to determine the antioxidant status of patients with FEP and its potential relationship with the transcription factor Nrf2; this would allow to investigate the pathophysiology of this condition and identify new pharmacological targets.

Conclusions {#sec013}
===========

In brief, our data indicates that, in the early stages of the illness, FEP patients with a poorer clinical status have a lower antioxidant capacity but in the long term, this correlation is reversed and their antioxidant defence capacity seems to improve as a compensatory response mechanism of the body. This finding should be seriously considered, as it suggests that the antioxidant treatments currently under study should be only applied during the early stages of the illness or, at least, their long-term use is more questionable.

Supporting information {#sec014}
======================

###### Potential confounding factors tested in in the three TAS measurements.

NA = not applicable.

(DOCX)

###### 

Click here for additional data file.

###### Relationship between total antioxidant status (TAS) and Young Mania Rating Scale (YMRS) scores over a two year follow-up.

(TIF)

###### 

Click here for additional data file.

###### Relationship between total antioxidant status (TAS) and the positive syndrome scale (PANSS Pos) scores over a two year follow-up.

(TIF)

###### 

Click here for additional data file.
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